Clinical trial · Interventional
Safety and Efficacy of a New Approach to Delineating Clinical Target Volume of Glioblastoma
Safety and Efficacy of a New Approach to Delineating Clinical Target Volume by Referencing the Nerve Fiber Bundles for Radiotherapy of Glioblastoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Radiotherapy (RT) is one of the most important local treatments besides surgery, but currently, no consensus has been made regarding the optimal radiation volume for high grade gliomas. The most main growth characteristics of glioblastoma is infiltrative growth through the white matter tracts, regions along the white matter tracts especially at the direction of the main fiber bundles would have a higher risk of microscopic tumor cell dissemination. However, in current practice, recommends for the CTV definition is adding a 2 cm symmetrical margin to GTV or peritumoral edema in all directions, which hardly account for the growth characteristics of gliomas that are known from histopathological findings.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| New delineation approach | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- New delineation approach （NDA）group
- description
- use a new method for clinical target volume delineation by referencing the nerve fiber bundles
- interventionNames
- Radiation: New delineation approach
Primary outcomes (1)
- measure
- Overall survival (OS)
- timeFrame
- 2 years
- description
- Time from the start of treatment to death due to the disease
Secondary outcomes (1)
- measure
- recurrence-free survival (RFS)
- timeFrame
- 1 year
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Age between 18-70 years * performance status of 0-1 (Eastern Cooperative Oncology Group performance status) * histologically confirmed glioblastoma * no cerebrospinal fluid and distant metastatic disease * All patients had adequate hematologic, hepatic, and renal function. Exclusion Criteria: * younger than 18 years; * patients with a prior (i.e. within 5 years) or synchronous malignancy, other than non-melanoma skin cancer; and those with significant comorbidities
References
Publications (0)
Data not yet available